Mercader García, PedroPastor-Nieto, MaríaGonzález-Pérez, RicardoGiménez Arnau, Anna MariaRuiz-Gonzalez, InmaculadaMora-Fernández, VerónicaMiquel, JavierSilvestre Salvador, Juan FranciscoSanz-Sánchez, TatianaPerez-Feal, PatriciaSánchez-Pérez, JavierHeras-Mendaza, FelipeSerra-Baldrich, EstherHervella Garcés, MarcosGatica-Ortega, María-ElenaGarcía-Doval, IgnacioBorrego, Leopoldo2022-01-182021Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Gimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Sanz-Sanchez T, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, Borrego L. Arguments in favour of excluding MDBGN from the European baseline series. In response to "Comment on MDBGN/DBDCB, the European baseline series, and EU legislation". Contact Dermatitis. 2021;85(5):611-3. DOI: 10.1111/cod.139410105-1873http://hdl.handle.net/10230/52245application/pdfengThis is the peer reviewed version of the following article: Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Gimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Sanz-Sanchez T, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, Borrego L. Arguments in favour of excluding MDBGN from the European baseline series. In response to "Comment on MDBGN/DBDCB, the European baseline series, and EU legislation". Contact Dermatitis. 2021;85(5):611-3. DOI: 10.1111/cod.13941, which has been published in final form at http://dx.doi.org/10.1111/cod.13941. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1111/cod.13941Allergic contact dermatitisEpidemiologyMethyldibromo glutaronitrileinfo:eu-repo/semantics/openAccess